Receipt of Opioid Analgesics by HIV-Infected and Uninfected Patients
- 466 Downloads
Opioids are increasingly prescribed, but there are limited data on opioid receipt by HIV status.
To describe patterns of opioid receipt by HIV status and the relationship between HIV status and receiving any, high-dose, and long-term opioids.
Cross-sectional analysis of the Veterans Aging Cohort Study.
HIV-infected (HIV+) patients receiving Veterans Health Administration care, and uninfected matched controls.
Pain-related diagnoses were determined using ICD-9 codes. Any opioid receipt was defined as at least one opioid prescription; high-dose was defined as an average daily dose ≥120 mg of morphine equivalents; long-term opioids was defined as ≥90 consecutive days, allowing a 30 day refill gap. Multivariable models were used to assess the relationship between HIV infection and the three outcomes.
Among the HIV+ (n = 23,651) and uninfected (n = 55,097) patients, 31 % of HIV+ and 28 % of uninfected (p < 0.001) received opioids. Among patients receiving opioids, HIV+ patients were more likely to have an acute pain diagnosis (7 % vs. 4 %), but less likely to have a chronic pain diagnosis (53 % vs. 69 %). HIV+ patients received a higher mean daily morphine equivalent dose than uninfected patients (41 mg vs. 37 mg, p = 0.001) and were more likely to receive high-dose opioids (6 % vs. 5 %, p < 0.001). HIV+ patients received fewer days of opioids than uninfected patients (median 44 vs. 60, p < 0.001), and were less likely to receive long-term opioids (31 % vs. 34 %, p < 0.001). In multivariable analysis, HIV+ status was associated with receipt of any opioids (AOR 1.40, 95 % CI 1.35, 1.46) and high-dose opioids (AOR 1.22, 95 % CI 1.07, 1.39), but not long-term opioids (AOR 0.94, 95 % CI 0.88, 1.01).
Patients with HIV infection are more likely to be prescribed opioids than uninfected individuals, and there is a variable association with pain diagnoses. Efforts to standardize approaches to pain management may be warranted in this highly complex and vulnerable patient population.
KEY WORDSopioid pain HIV narcotics veterans
This work was generously supported by the Society of General Internal Medicine’s Lawrence Linn Award, the Robert Wood Johnson Foundation Clinical Scholars Program, the Department of Veterans Affairs and the Veterans Aging Cohort study, funded by the National Institute on Alcohol Abuse and Alcoholism (U10 AA 13566).
This work was presented as oral presentations in earlier versions at the Veterans Aging Cohort Study Scientific Meeting, October 13th, 2011, Washington, D.C. and the Society of General Internal Medicine 35th National Annual Meeting, May 12th, 2012, Orlando, FL.
The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs.
Conflict of Interest
The authors declare that they do not have a conflict of interest.
- 1.Trescot AM, Helm S, Hansen H, et al. Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians’ (ASIPP) Guidelines. Pain Phys. 2008;11(2 Suppl):S5–62.Google Scholar
- 7.Onen NF, Barrette EP, Shacham E, Taniguchi T, Donovan M, Overton ET. A review of opioid prescribing practices and associations with repeat opioid prescriptions in a contemporary outpatient HIV clinic. Pain Pract. Nov 22 2011.Google Scholar
- 12.Silverberg MJ, Ray GT, Saunders K, et al. Prescription long-term opioid use in HIV-infected patients. Clin J Pain. Jun 14 2011.Google Scholar
- 14.Koeppe J, Lichtenstein K, Armon C, et al. Factors associated with initiation of prolonged analgesic use among patients in the HIV Outpatient Study (HOPS). Clin J Pain. May 2 2011.Google Scholar
- 15.Miaskowski C, Penko JM, Guzman D, Mattson JE, Bangsberg DR, Kushel MB. Occurrence and characteristics of chronic pain in a community-based cohort of indigent adults living with HIV infection. J Pain. Jun 17 2011.Google Scholar
- 18.Roy S, Ninkovic J, Banerjee S, et al. Opioid drug abuse and modulation of immune function: consequences in the susceptibility to opportunistic infections. J Neuroimmune Pharmacol. Jul 26 2011.Google Scholar
- 24.Tetrault JM, Tate JP, McGinnis KA, et al. Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone. Alcohol Clin Exp Res. Jul 28 2011.Google Scholar
- 29.Centers for Medicare and Medicaid Services. ICD-9 Provider and Diagnostic Codes. 2011; https://www.cms.gov/icd9providerdiagnosticcodes/. Accessed 7-14-2012.
- 31.Agency Medical Directors’ Group. Interagency guideline on opioid dosing for chronic non-cancer pain. June 2010.Google Scholar
- 34.U.S. Drug Enforcement Adminstration. Controlled Substance Schedules. http://www.deadiversion.usdoj.gov/schedules/index.html, 2010. Accessed 7.14.2012.
- 36.Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for Adults and Adolescents D. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. In: (OARAC) OoARAC, ed2012.Google Scholar
- 42.Sinnott PL, Siroka AM, Shane AC, Trafton JA, Wagner TH. Identifying neck and back pain in administrative data: defining the right cohort. Spine (Phila Pa 1976). Nov 26 2011.Google Scholar
- 46.Edelman EJ, Gordon K, Justice AC. Patient and provider-reported symptoms in the post-cART Era. AIDS Behav. May 20 2010.Google Scholar